COCO vs. KNSA
COCO (The Vita Coco Company, Inc.) and KNSA (Kiniksa Pharmaceuticals, Ltd.) are both stocks. COCO operates in Beverages - Non-Alcoholic (Consumer Defensive), while KNSA operates in Biotechnology (Healthcare). Over the past 3 years, COCO returned 42.82%/yr vs 52.43%/yr for KNSA. At a 0.15 correlation, their price movements are largely independent.
Performance
COCO vs. KNSA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, COCO achieves a 58.50% return, which is significantly higher than KNSA's 33.60% return.
COCO
- 1D
- 0.45%
- 1M
- 10.49%
- YTD
- 58.50%
- 6M
- 57.11%
- 1Y
- 139.24%
- 3Y*
- 42.82%
- 5Y*
- —
- 10Y*
- —
KNSA
- 1D
- 1.66%
- 1M
- 3.51%
- YTD
- 33.60%
- 6M
- 27.60%
- 1Y
- 93.78%
- 3Y*
- 52.43%
- 5Y*
- 29.69%
- 10Y*
- —
COCO vs. KNSA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
COCO The Vita Coco Company, Inc. | 58.50% | 43.62% | 43.90% | 85.60% | 23.72% | -27.33% |
KNSA Kiniksa Pharmaceuticals, Ltd. | 33.60% | 108.54% | 12.77% | 17.09% | 27.27% | 8.28% |
Correlation
The correlation between COCO and KNSA is 0.11, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.11 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.10 |
Correlation (All Time) Calculated using the full available price history since Oct 21, 2021 | 0.15 |
Fundamentals
COCO:
$5.08B
KNSA:
$4.54B
COCO:
$1.38
KNSA:
$0.92
COCO:
60.89
KNSA:
59.85
COCO:
0.51
KNSA:
0.58
COCO:
7.67
KNSA:
5.80
COCO:
14.43
KNSA:
7.50
COCO:
$658.62M
KNSA:
$754.05M
COCO:
$246.32M
KNSA:
$294.06M
COCO:
$100.45M
KNSA:
$101.06M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
COCO vs. KNSA — Risk / Return Rank
COCO
KNSA
COCO vs. KNSA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for The Vita Coco Company, Inc. (COCO) and Kiniksa Pharmaceuticals, Ltd. (KNSA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| COCO | KNSA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.34 | ||
| Sortino ratioReturn per unit of downside risk | +0.02 | ||
| Omega ratioGain probability vs. loss probability | 1.44 | 1.41 | +0.03 |
| Calmar ratioReturn relative to maximum drawdown | 5.86 | 4.63 | +1.23 |
| Martin ratioReturn relative to average drawdown | 16.41 | 16.35 | +0.06 |
Loading charts...
Drawdowns
COCO vs. KNSA - Drawdown Comparison
The maximum COCO drawdown since its inception was -56.97%, smaller than the maximum KNSA drawdown of -83.06%. Use the drawdown chart below to compare losses from any high point for COCO and KNSA.
Loading charts...
Drawdown Indicators
| COCO | KNSA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -56.97% | -83.06% | +26.09% |
Max Drawdown (1Y)Largest decline over 1 year | -23.23% | -21.12% | -2.11% |
Max Drawdown (3Y)Largest decline over 3 years | -38.55% | -34.14% | -4.41% |
Max Drawdown (5Y)Largest decline over 5 years | — | -53.17% | — |
Current DrawdownCurrent decline from peak | 0.00% | -7.35% | +7.35% |
Average DrawdownAverage peak-to-trough decline | -16.76% | -40.60% | +23.84% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.28% | 5.97% | +2.31% |
Volatility
COCO vs. KNSA - Volatility Comparison
The current volatility for The Vita Coco Company, Inc. (COCO) is 9.69%, while Kiniksa Pharmaceuticals, Ltd. (KNSA) has a volatility of 10.40%. This indicates that COCO experiences smaller price fluctuations and is considered to be less risky than KNSA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| COCO | KNSA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.69% | 10.40% | -0.71% |
Volatility (6M)Calculated over the trailing 6-month period | 41.61% | 34.02% | +7.59% |
Volatility (1Y)Calculated over the trailing 1-year period | 52.25% | 43.03% | +9.22% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 56.71% | 53.48% | +3.23% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 56.71% | 63.93% | -7.22% |
Dividends
COCO vs. KNSA - Dividend Comparison
Neither COCO nor KNSA has paid dividends to shareholders.
Financials
COCO vs. KNSA - Financials Comparison
This section allows you to compare key financial metrics between The Vita Coco Company, Inc. and Kiniksa Pharmaceuticals, Ltd.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
COCO vs. KNSA - Profitability Comparison
COCO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, The Vita Coco Company, Inc. reported a gross profit of 71.81M and revenue of 179.77M. Therefore, the gross margin over that period was 40.0%.
KNSA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Kiniksa Pharmaceuticals, Ltd. reported a gross profit of 0.00 and revenue of 214.27M. Therefore, the gross margin over that period was 0.0%.
COCO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, The Vita Coco Company, Inc. reported an operating income of 33.58M and revenue of 179.77M, resulting in an operating margin of 18.7%.
KNSA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Kiniksa Pharmaceuticals, Ltd. reported an operating income of 29.27M and revenue of 214.27M, resulting in an operating margin of 13.7%.
COCO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, The Vita Coco Company, Inc. reported a net income of 30.47M and revenue of 179.77M, resulting in a net margin of 17.0%.
KNSA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Kiniksa Pharmaceuticals, Ltd. reported a net income of 22.59M and revenue of 214.27M, resulting in a net margin of 10.5%.
Frequently Asked Questions
COCO and KNSA have a correlation of 0.11, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
KNSA has higher volatility (10.40%) compared to COCO (9.69%). In terms of maximum drawdown, COCO dropped -56.97% vs KNSA's -83.06%.
COCO currently has the higher Sharpe Ratio (2.61 vs 2.27), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for COCO and KNSA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer